Quantify’s collaboration with Harvey Norman is a win-win

Published 18-JUL-2018 13:51 P.M.

|

4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Quantify Technology Holdings Ltd (ASX:QFY) continues to see dividends from its established agreement with Harvey Norman Commercial Division (HNCD) regarding the promotion and distribution of its platform to commercial and residential development projects throughout NSW and the ACT.

The agreement also involves the development of a demonstration facility at HNCD’s showroom in NSW.

Recently, the company’s engineers were on-site in Sydney, fitting out HNCD’s demonstration suite at the prestigious Burcham development.

Proprietary technology taps into IOT industry

As a backdrop, QFY is an Australian-based pioneer of Truly Intelligent Buildings technology.

The company has created simple to install, affordable Internet of Things (IOT) devices that encourage wide-scale adoption of IOT solutions.

QFY’s commercial product known as the Q Device replaces standard power outlets and light switches in commercial and residential structures. As it uses standard Alternating Current (AC) wiring, it can be easily retrofitted without re-cabling in existing buildings.

It should be noted, however, that this is an early stage tech company and success is no guarantee. Investors should seek professional financial advice before making an investment.

The Q Device replaces AC light switches/dimmers and power outlets with an intelligent, network-connected framework to provide energy management and reporting, voice-enabled control and interaction, and real-time evaluation of environmental and risk factors for building occupants.

Residential applications with scalability and flexibility

Located in the much-sought-after Rosebery suburb, the apartment will showcase the residential application, scalability, and flexibility of QFY’s framework, as well its enterprise applications.

Though installation was originally anticipated to commence in April 2018, HNCD only recently took possession of the apartment and the project is on schedule with final commissioning to be completed in the coming weeks.

Harvey Norman acknowledges Smart Home Automation

One of the most promising developments to note as QFY continues to evolve from research and development to product adoption and sales is the strong uptake of its devices.

“Seeing a next-generation platform of this calibre installed in our Burcham display apartment has shown us what the gold standard of the future can and should be,” said HNCD Smart Home Automation Manager Kris Leffler.

“Quantify Technology has developed the must-have solution for new and existing construction.

“Working together, Harvey Norman and Quantify Technology will only continue to expand and enhance technology innovations for our commercial partners and consumers.”

HNCD a conduit to residential and commercial markets

Not only are QFY’s solutions an important sales tool for HNCD, with Harvey Norman’s brand power and an active sales force behind it, the company’s products should be efficiently distributed into the residential and commercial construction markets.

HNCD has made smart homes of the future a focus of their expanding reach in the residential and commercial construction sectors.

On this note, QFY’s Managing Director Mark Lapins said, “Working with Australian icons like Harvey Norman is an honour, especially when they’re setting trends and exceeding expectations in the Australian market and beyond.”

Shares in QFY have performed strongly this week, increasing 20 per cent from last week’s close of 2.5 cents to hit an intraday high of 3 cents on Tuesday.

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

Should the company continue with the frequent positive news flow regarding its entry into multiple sectors there is the possibility for this momentum to be sustained.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X